Sign in

CIK 0001806310 · Non-accelerated filer<br>Smaller reporting company

Taysha Gene Therapies, Inc.

Sign in to watch
Ticker
TSHA
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
843199512
Phone
(214) 612-0000
Business address
3000 PEGASUS PARK DRIVE, SUITE 1430, DALLAS, TX, 75247
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$0
in 0 filings

Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Reading 7 more Form 4s from the SEC; this list fills in as they're read.

Date Insider Transaction Shares Price Value Owned after
2021-01-19 Session R.A. II President and CEO Grant or award · Stock Option (Right to Buy) +199,700 199,700
2021-01-19 PRASAD SUYASH CMO and Head of R&D Grant or award · Stock Option (Right to Buy) +80,000 80,000
2021-01-19 Alam Kamran Chief Financial Officer Grant or award · Stock Option (Right to Buy) +70,000 70,000
2020-11-23 Sepp-Lorenzino Laura Director Grant or award · Stock Option (right to buy) +31,000 31,000
2020-11-23 Reape Kathleen Director Grant or award · Stock Option (right to buy) +31,000 31,000
2020-09-28 PRASAD SUYASH CMO and Head of R&D Conversion +3,844 672,589
2020-09-28 PRASAD SUYASH CMO and Head of R&D Conversion · Series B Preferred Stock −3,529 0
2020-09-28 Nolan Sean P. Director Conversion +1,089,500 1,089,500
2020-09-28 Nolan Sean P. Director Conversion +1,601 1,091,101
2020-09-28 Nolan Sean P. Director Conversion · Series A Preferred Stock −1,000,000 0
2020-09-28 Nolan Sean P. Director Conversion · Series B Preferred Stock −1,470 0
2020-09-28 Nagendran Sukumar Director Conversion +19,226 19,226
2020-09-28 Nagendran Sukumar Director Conversion · Series B Preferred Stock −17,647 0

Page 9 of 9 · 173 trades